Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 5/2010

01-09-2010

The Resuscitation Package in Sepsis

Authors: Lee M. Demertzis, Marin H. Kollef

Published in: Current Infectious Disease Reports | Issue 5/2010

Login to get access

Abstract

Sepsis and its attendant complications are commonly encountered in the intensive care unit. Early recognition of sepsis is critical because it allows for rapid deployment of a multifaceted resuscitation package. The cornerstones of sepsis management are antibiotic therapy, source control, and hemodynamic resuscitation. In select patients, ancillary therapies are indicated, such as activated protein C, corticosteroids, and glycemic control. Given the complexity of sepsis management, optimal care can be delivered as a bundle—a protocol encompassing the above interventions. The evidence behind the various components of sepsis management are reviewed here.
Literature
1.
Bone RC, Balk RA, Cerra FB, et al.: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992, 101:1644–1655.CrossRefPubMed
2.
Kumar A, Roberts D, Wood KE, et al.: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589–1596.CrossRefPubMed
3.
Ferrer R, Artigas A, Suarez D, et al.: Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009, 180:861–866.CrossRefPubMed
4.
Kumar A, Ellis P, Arabi Y, et al.: Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009, 136:1237–1248.CrossRefPubMed
5.
Harbarth S, Garbino J, Pugin J, et al.: Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003, 115:529–535.CrossRefPubMed
6.
Ibrahim EH, Sherman G, Ward S, et al.: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146–155.CrossRefPubMed
7.
Marshall JC, Lowry SF: Evaluation of the adequacy of source control in clinical trials in sepsis. In Clinical Trials for the Treatment of Sepsis. Edited by Sibbald WJ, Vincent JL. New York: Springer-Verlag; 1995:327–344.
8.
Marshall JC, Maier RV, Jimenez M, et al.: Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004, 32(Suppl):S513–S526.CrossRefPubMed
9.
Vincent JL, Gerlach H: Fluid resuscitation in severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004, 32(Suppl):S451–S454.CrossRefPubMed
10.
Finfer S, Bellomo R, Boyce N, et al.: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004, 350:2247–2256.CrossRefPubMed
11.
Brunkhorst FM, Engel C, Bloos F, et al.: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358:125–139.CrossRefPubMed
12.
•• Dellinger RP, Levy MM, Carlet JM, et al.: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296–327. This article is a high-quality, evidence-based review of management of severe sepsis and septic shock.
13.
Rivers E, Nguyen B, Havstad S, et al.: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368–1377.CrossRefPubMed
14.
Marik PE, Baram M, Vahid B: Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest 2008, 134:172–178.CrossRefPubMed
15.
Pfeiffer U, Perker M, Zeravik J, et al.: Sensitivity of central venous pressure, pulmonary capillary wedge pressure and intrathoracic blood volume as indicators for acute and chronic hypovolemia. In Practical Applications of Fiberoptics in Critical Care Monitoring. Edited by Lewis F, Pfeiffer U. New York: Springer-Verlag; 1990:25–31.
16.
Knobloch K, Lichtenberg A, Winterhalter M, et al.: Non-invasive cardiac output determination by two-dimensional independent Doppler during and after cardiac surgery. Ann Thorac Surg 2005, 80:1479–1484.CrossRefPubMed
17.
Chand R, Mehta Y, Trehan N: Cardiac output estimation with a new Doppler device after off-pump coronary artery bypass surgery. J Cardiothorac Vascular Anesth 2006, 20:315–319.CrossRef
18.
Tan HL, Pinder M, Parsons R, et al.: Clinical evaluation of USCOM ultrasonic cardiac output monitor in cardiac surgical patients in intensive care unit. Brit J Anaesth 2005, 94:287–291.CrossRefPubMed
19.
Su BC, Lin CC, Su CW, et al.: Ultrasonic cardiac output monitor provides accurate measurement of cardiac output in recipients after liver transplantation. Acta Anaesthesiol Taiwan 2008, 46:171–177.CrossRefPubMed
20.
Wong LS, Yong BH, Young KK, et al.: Comparison of the USCOM ultrasound cardiac output monitor with pulmonary artery catheter thermodilution in patients undergoing liver transplantation. Liver Transpl 2008, 14:1038–1043.CrossRefPubMed
21.
Wiedemann HP, Wheeler AP, Bernard GR, et al.: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006, 354:2564–2575.CrossRefPubMed
22.
Murphy CV, Schramm GE, Doherty JA, et al.: The importance of fluid management in acute lung injury secondary to septic shock. Chest 2009, 136:102–109.CrossRefPubMed
23.
LeDoux D, Astiz ME, Carpati CM, et al.: Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med 2000, 28:2729–2732.CrossRefPubMed
24.
Russell JA, Walley KR, Singer J, et al.: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008, 358:877–887.CrossRefPubMed
25.
Griffin JH, Fernández JA, Gale AJ, et al.: Activated protein C. J Thromb Haemost 2007, 5(Suppl 1):S73–S80.CrossRef
26.
Levi M, van der Poll T: Recombinant human activated protein C: current insights into its mechanism of action. Crit Care 2007, 11(Suppl 5):S3.CrossRefPubMed
27.
• Toussaint S, Gerlach H: Activated protein C for sepsis. N Engl J Med 2009, 361:2646–2652. This article provides an evidence-based review of activated protein C and its use in severe sepsis.
28.
Bernard GR, Vincent JL, Laterre PF, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699–709.CrossRefPubMed
29.
Ely EW, Laterre PF, Angus DC, et al.: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003, 31:12–19.CrossRefPubMed
30.
Abraham E, Laterre PF, Garg R, et al.: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332–1341.CrossRefPubMed
31.
Laterre PF: Clinical trials in severe sepsis with drotrecogin alfa (activated). Crit Care 2007, 11(Suppl 5):S5.CrossRefPubMed
32.
Bone RC, Fisher CJ, Clemmer TP, et al.: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987, 317:653–658.CrossRefPubMed
33.
The Veterans Administration Systemic Sepsis Cooperative Study Group: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987, 317:659–665.CrossRef
34.
Cronin L, Cook DJ, Carlet J, et al.: Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature. Crit Care Med 1995, 23:1430–1439.CrossRefPubMed
35.
Annane D, Sébille V, Charpentier C, et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288:862–871.CrossRefPubMed
36.
•• Sprung CL, Annane D, Keh D, et al.: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008, 358:111–124. This article describes the CORTICUS trial, a randomized, controlled trial that showed no mortality benefit with corticosteroid therapy in septic shock, regardless of the results of a corticotropin test.
37.
Inzucchi SE: Management of hyperglycemia in the hospital setting. N Engl J Med 2006, 355:1903–1911.CrossRefPubMed
38.
Van den Berghe G, Wouters P, Weekers F, et al.: Intensive insulin therapy in critically ill patients. N Engl J Med 2001, 345:1359–1367.CrossRefPubMed
39.
Van den Berghe G, Wilmer A, Hermans G, et al.: Intensive insulin therapy in the medical ICU. N Engl J Med 2006, 354:449–461.CrossRefPubMed
40.
Preiser JC, Devos P, Ruiz-Santana S, et al.: A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med 2009, 35:1738–1748.CrossRefPubMed
41.
•• Finfer S, Chittock DR, Su SY, et al.: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360:1283–1297. This article describes the NICE-SUGAR study, a large, multicenter, randomized, controlled trial that showed evidence of harm in critically ill patients treated with intensive insulin therapy to maintain euglycemia.
42.
Barochia AV, Cui X, Vitberg D, et al.: Bundled care for septic shock: an analysis of clinical trials. Crit Care Med 2010, 38:668–678.CrossRefPubMed
43.
•• Ferrer R, Artigas A, Levy MM, et al.: Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 2008, 299:2294–2303. This article describes a before-and-after study showing improved sepsis bundle compliance rates and consequent in-hospital mortality following an educational intervention.
44.
Micek ST, Roubinian N, Heuring T, et al.: Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med 2006, 34:2707–2713.CrossRefPubMed
45.
Thiel SW, Asghar MF, Micek ST, et al.: Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis. Crit Care Med 2009, 37:819–824.CrossRefPubMed
Metadata
Title
The Resuscitation Package in Sepsis
Authors
Lee M. Demertzis
Marin H. Kollef
Publication date
01-09-2010
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 5/2010
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-010-0121-4

Other articles of this Issue 5/2010

Current Infectious Disease Reports 5/2010 Go to the issue

Clinical Trial Report

Clinical Trial Report—Polymyxin B Hemoperfusion: Effective, or Not?

OriginalPaper

Adjunct Therapy for Sepsis: How Early?

ReviewPaper

Nonbacterial Myositis

ReviewPaper

Early Fluid Resuscitation

OriginalPaper

Early Identification of Sepsis

ReviewPaper

Clostridial Myonecrosis: New Insights in Pathogenesis and Management
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits